Countering anthrax: Vaccines and immunoglobulins

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 129-136

  Grabenstein, John D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABTHRAX; ALUMINUM HYDROXIDE; ANTHIM; ANTHRAX ANTIBODY; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTISERUM; BACTERIAL ANTIGEN; EXOTOXIN; MONOCLONAL ANTIBODY; PENICILLIN G; POLYCLONAL ANTIBODY; PROTECTIVE ANTIGEN; RAXIBACUMAB; RECOMBINANT VACCINE; SULFANILAMIDE; UNCLASSIFIED DRUG; VALTORIM; IMMUNOGLOBULIN;

ACTIVE IMMUNIZATION; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIGEN SPECIFICITY; ARTHRALGIA; BACILLUS ANTHRACIS; BACTERIAL SPORE; BIOLOGICAL WARFARE; BURNING SENSATION; CLINICAL FEATURE; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; HUMAN; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MYALGIA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION; VACCINATION REACTION; IMMUNOLOGY; METHODOLOGY; MULTIDRUG RESISTANCE;

ANTHRAX; ANTHRAX VACCINES; ANTIBIOTIC PROPHYLAXIS; BACILLUS ANTHRACIS; BIOTERRORISM; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; SPORES, BACTERIAL; VACCINATION;

EID: 39349106837     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523578     Document Type: Review

References (49)

1. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019-28.
2. Langmuir AD. Biological warfare defense. 2. The Epidemic Intelligence Service of the Communicable Disease Center. Am J Public Health 1952; 42:235-8.
3. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287:2236-52.
4. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994; 266:1202-8.
5. Turnbull PCB. Guidelines for the surveillance and control of anthrax in humans and animals. 3rd ed. WHO/EMC/ZDI/98.6. Geneva, Switzerland: World Health Organization, 1998.
6. Brachman PS, Friedlander AM, Grabenstein JD. Anthrax. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Elsevier, 2003:887-903.
7. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerging Infect Dis 2002; 8:222-5.
8. Advisory Committee on Immunization Practices. Use of anthrax vaccine in the United States. MMWR Recomm Rep 2000; 49(RR-15):1-20.
9. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26.
10. Schwartz MN. Recognition and management of anthrax: an update. N Engl J Med 2001; 345:1621-6.
11. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006; 144:270-80.
12. Parish HJ. A history of immunizations. Edinburgh and London: E&S Livingstone, 1965:42-50.
13. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991;9:533-9.
14. Joellenbeck LM, Zwanziger L, Durch JS, Strom BL, eds. The anthrax vaccine: is it safe? Does it work? Washington, DC: National Academy Press, 2002.
15. US Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; final order. Fed Reg 2005; 70:75180-98.
16. Baillie LW. Past, imminent, and future human medical countermeasures for anthrax. J Appl Microb 2006; 101:594-606.
17. Grabenstein JD, Pittman PR, Greenwood JT, Engler RJM. Immunization to protect the US armed forces: heritage, current practice, prospects. Epidemiol Rev 2006; 28:3-26.
18. Brachman PS, Gold H, Plotkin SA, Fekety FK, Werrin M, Ingram NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:632-45.
19. Pittman PR, Kim-Ahn G, Pifat DY, et al. Anthrax vaccine: safety and immunogenicity of a dose-reduction, route-comparison study in humans. Vaccine 2002; 20:1412-20.
20. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006; 24:3654-60.
21. Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull 1996; 87(Suppl):125-6.
22. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999; 282:2104-6.
23. Pitt MLM, Ivins BE, Estep JE, Farchaus J, Friedlander AM. Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax. Salisbury Med Bull 1996; 87(Suppl):130.
24. Ivins BE, Pitt MLM, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998; 16:1141-8.
25. Fellows PF, Linscott MK, Ivins BE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001; 19:3241-7.
26. Pitt MLM, Little SF, Ivins BE, et al. In vitro correlation of immunity in a rabbit model of inhalational anthrax. Vaccine 2001; 19:4768-73.
27. Grabenstein JD. ImmunoFacts: vaccines and immunologic drugs. 32nd ed. Saint Loui, MO: Wolters Kluwer, 2007.
28. Friedlander AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239-43.
29. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond) 1956;54:28-36.
30. Gochenour WS Jr, Sawyer WD, Henderson JE, Gleiser CA, Kuehne RW, Tigertt WD. On the recognition and therapy of simian woolsorter's disease. J Hyg Cambridge 1963; 61:317-25.
31. Glassman HN. Industrial inhalation anthrax: discussion. Bacteriol Rev 1966; 30:657-9.
32. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001; 20:972-8.
33. Wasserman GM, Grabenstein JD, Pittman PR, et al. Analysis of adverse events after anthrax vaccination in U.S. army medical personnel. J Occup Environ Med 2003; 45:222-33.
34. Hoffman K, Costello C, Menich M, Grabenstein JD, Engler RJM. Using a structured medical note for determining the safety profile of anthrax vaccine for US soldiers in Korea. Vaccine 2003; 21:4399-409.
35. Lange JL, Lesikar SE, Brundage JF, Rubertone MV. Comprehensive systematic surveillance for adverse effects of anthrax vaccine adsorbed, U.S. armed forces, 1998-2000. Vaccine 2003; 21:1620-8.
36. Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US army women. JAMA 2002; 287:1556-60.
37. Sulsky SI, Grabenstein JD, Delbos RG. Disability among U.S. army personnel vaccinated against anthrax. J Occup Environ Med 2004; 46:1065-75.
38. Catherino WH, Levi A, Kao T-C, Leondires MP, McKeeby J, Segars JH. The anthrax vaccine does not affect semen parameters, embryo quality, or pregnancy outcome in couples with a vaccinated male military service member. Fertility and Sterility 2005; 83:480-3.
39. Pittman PR, Coonan KM, Gibbs PH, Scott HM, Cannon TL, McKee KT Jr. Long-term health effects of repeated exposure to multiple vaccines. Vaccine 2004; 23:525-36.
40. Sever JL, Brenner AI, Gale AD, et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2004; 13:825-40.
41. Hunter D, Zoutman D, Whitehead J, Hutchings J. Health effects of anthrax vaccination in the Canadian Forces. Mil Med 2004; 169:833-8.
42. McNeil MM, Chiang IS, Wheeling JT, Zhang Y. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1955-2005 medical literature. Pharmacoepidemiol Drug Saf 2007; 16:259-74.
43. Payne DC, Franzke LH, Stehr-Green PA, Schwartz B, McNeil MM. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiol Drug Saf 2007; 16:46-54.
44. Smith B, Leard CA, Smith TC, Reed RJ, Ryan MA; Millennium Cohort Study Team. Anthrax vaccination in the Millennium Cohort: validation and measures of health. Am J Prev Med 2007; 32:347-53.
45. Regan JC. The advantage of serum therapy as shown by a comparison of various methods of treatment of anthrax. Am J Med Sci 1921; 162:406-23.
46. Gold H. Anthrax: a report of one hundred seventeen cases. Arch Intern Med 1955; 96:387-96.
47. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968-71.
48. Keitel W. Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine. Expert Rev Vaccines 2006; 5:417-30.
49. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005; 41:12-20.